Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
IM92
i
Other names:
IM92
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Beijing Imunopharm
Drug class:
CLDN18.2-targeted CAR-T immunotherapy
Related drugs:
‹
CT041 (4)
IBI-345 (3)
AZD6422 (0)
CT048 (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
HEC-016 (0)
IMC002 (0)
IMC008 (0)
KD-182 (0)
KD-496 (0)
LCAR-C18S (0)
LY011 (0)
XKDCT086 (0)
anti-Claudin 18.2 CAR-T cell therapy (0)
CT041 (4)
IBI-345 (3)
AZD6422 (0)
CT048 (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
HEC-016 (0)
IMC002 (0)
IMC008 (0)
KD-182 (0)
KD-496 (0)
LCAR-C18S (0)
LY011 (0)
XKDCT086 (0)
anti-Claudin 18.2 CAR-T cell therapy (0)
›
Associations
News
Trials
Filter by
Latest
2years
Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma (clinicaltrials.gov)
P1, N=6, Recruiting, Beijing Immunochina Medical Science & Technology Co., Ltd.
2 years ago
New P1 trial • CAR T-Cell Therapy • IO biomarker
|
CLDN18 (Claudin 18) • CA 19-9 (Cancer antigen 19-9)
|
CLDN18.2 positive
|
IM92
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login